Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 1/2012

01-01-2012 | Meeting report

Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25–27, 2011, Mainz, Germany

Authors: Kathleen Hobohm, Torsten Seppmann, Cedrik M. Britten, Holger Hoff

Published in: Cancer Immunology, Immunotherapy | Issue 1/2012

Login to get access

Excerpt

CIMT 2011 was the ninth annual meeting organized by the Association for Cancer Immunotherapy (CIMT). More than 500 international participants met in Mainz, Germany, to discuss the latest topics in cancer immunotherapy. A total of 176 posters were presented by young scientists, and several of them were selected for short talk sessions. Three industry satellite symposia provided insights into new developments in state-of-the-art technologies to enhance cancer immunotherapy. The major topics of CIMT 2011 were trends in cellular therapies, therapeutic vaccination, improving immunity, immunoguiding, regulatory research and optimizing early clinical trials. This meeting report summarizes selected presentations to give an overview over the fields discussed during the meeting. …
Metadata
Title
Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25–27, 2011, Mainz, Germany
Authors
Kathleen Hobohm
Torsten Seppmann
Cedrik M. Britten
Holger Hoff
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 1/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1131-2

Other articles of this Issue 1/2012

Cancer Immunology, Immunotherapy 1/2012 Go to the issue

Focussed Research Review

A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens

Original article

Widespread expressions of immunoglobulin superfamily proteins in cancer cells

Original article

HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response

Original article

Interleukin-7 up-regulates cyclin D1 via activator protein-1 to promote proliferation of cell in lung cancer

Original article

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy

Opinion Paper

Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits